<DOC>
	<DOCNO>NCT00006454</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know paclitaxel plus carboplatin effective without topotecan ovarian epithelial cancer . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel plus carboplatin without topotecan treating patient stage IIB , stage III , stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Paclitaxel Plus Carboplatin With Without Topotecan Treating Patients With Stage IIB , Stage III , Stage IV Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient stage IIB , III , IV ovarian epithelial carcinoma receive treatment paclitaxel carboplatin without topotecan . II . Compare progression-free survival patient receive treatment regimen . III . Compare response rate response duration patient treat regimen . IV . Determine toxic effect combination paclitaxel , carboplatin , topotecan patient . V. Compare toxic effect treatment regimens patient . VI . Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center stage ( stage IIB stage III optimally debulked great 1 cm residual tumor v stage IV regardless residual tumor residual tumor great 1 cm ) . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour carboplatin IV 0.5-1 hour day 1 topotecan IV 0.5 hour day 1-5 . Treatment repeat every 21 day 6 course ( topotecan administer 4 course ) . Arm II : Patients receive paclitaxel carboplatin arm I . Treatment repeat every 21 day 6 course . Quality life assess course 1 , 3 , 5 3 week 3 month completion treatment treatment arm ; course 1 3 topotecan arm I ; 6 month completion treatment arm II . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 914 patient ( 457 per treatment arm ) accrue study 2 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIB , III , IV ovarian epithelial carcinoma , fallopian tube , extraovarian papillary serous carcinoma extend ovary No mixed epithelial/nonepithelial tumor ( e.g. , mixed Mullerian tumor ) No tumor low malignant potential ( e.g. , borderline tumor ) No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.25 time ULN Estimated glomerular filtration rate least 60 mL/min Cardiovascular : No history congestive heart failure ( even medically control ) No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No history atrial ventricular arrhythmia Other : No motor sensory neurologic pathology symptom great grade 1 No active infection serious medical condition would preclude study No prior allergy drug contain Cremophor EL No dementia significantly alter mental state would preclude informed consent No complete bowel obstruction No prior malignancy except curatively treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent WBC transfusion Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No prior radiotherapy No concurrent radiotherapy Surgery : No 6 week since prior definitive laparotomy recover Other : No concurrent antineoplastic agent No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>